STAT+: Medicare Advantage growth dwindles for a second straight year
Stat News • 2/16/2026
Summary
Medicare Advantage growth has declined for a second consecutive year. In response to significant changes in the program, some large insurers are attempting to reduce their enrollment numbers.
Advertisement
Lindy Score Breakdown (V4.2)
46d
Age
1
Sources
from cluster
1104
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1104/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1104/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 46 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Medicare Advantage plans win extra $18.6 billion as feds cut star ratings measures
Stat News • Today
STAT+: The biotech scorecard for the second quarter: 23 stock-moving events to watch
Stat News • 2 days ago
STAT+: Makary marks one year at FDA with focus on achievements in speech to staff
Stat News • 1 day ago
Opinion: Medicare is restricting care for 1 million Americans based on a faulty assumption. Congress must intervene
Stat News • 2 days ago
STAT+: How health care could gum up Trump’s reconciliation push
Stat News • 1 day ago
STAT+: NIH director’s invocation of Vannevar Bush’s legacy to promote Trump science policies sparks pushback
Stat News • 2 days ago
STAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
Stat News • 1 day ago
Opinion: STAT+: Cardiology’s finally prioritizing prevention — but what will it look like?
Stat News • 1 day ago
STAT+: Can a psychedelic ‘coach’ make ketamine therapy even more effective?
Stat News • 2 days ago
STAT reporter goes up against radiologists to spot deepfake X-rays
Stat News • 1 day ago
Anti-Lindy Similar stories
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago